SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff has focused discussion on its heavy debt, costly financing needs and insider selling, alongside concerns about broader weakness in AI infrastructure stocks. Traders are split between fears of dilution or default and hopes that contracted AI demand, analyst support and buying near recent lows could underpin a recovery.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders pointing to upcoming share unlocks, reported insider selling, and a TD Cowen price-target cut as sources of pressure. The debate is whether the decline is temporary supply and AI-sector weakness or reflects deeper concerns about customer concentration, growth, and valuation; some traders see an oversold opportunity while others expect further downside.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat and raised full-year outlook, alongside improved medical-cost trends, are driving attention. Bulls view the results as evidence of a turnaround and welcome the rebound, while skeptics question whether the improvement will last and point to the stocks volatile reaction despite the strong report.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a sharp, prolonged pullback and a wider semiconductor selloff, with traders debating whether concerns about AI spending, financing, and returns signal a broader downturn. Many blame CEO Hock Tans comments likening AI investing to gambling for worsening sentiment, while others view the selloff as a buying opportunity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI-infrastructure stocks, fueled by concerns about neocloud financing, debt and whether heavy AI spending will generate sufficient returns. Traders are split on whether the rebound from oversold levels signals a recovery or a temporary bounce, with some arguing Nebius is better positioned than more debt-heavy peers.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a broad AI and semiconductor selloff, as traders debate whether heavy AI infrastructure spending and debt financing can generate adequate returns. Bulls point to continued chip demand and company announcements, while skeptics warn of an AI spending bubble and further sector weakness.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers steep selloff is dominated by concerns that its convertible-note financing and added shares will dilute investors, alongside weakness across AI and data-center infrastructure stocks. Bears question management, debt and execution, while some holders see the decline as an oversold pullback and remain bullish on the companys longer-term AI hosting opportunity.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb toward a 52-week high and a key round-number resistance level is driving discussion, with traders highlighting bullish chart momentum and a defensive rotation into pharma. Others question whether the move can hold, pointing to resistance and the absence of a single clear near-term catalyst.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure at new lows, with traders linking the decline to Trumps falling approval and approaching midterms. Discussion is largely bearish, though a few see a speculative buying opportunity, while others point to concerns about the companys media-business fundamentals.

Aventus Network

Aventuss disclosure that an attacker exploited a code vulnerability to mint and sell AVT has fueled attention to the tokens sharp swings in thin markets; the team says the exploit is patched and the attacker has exited. Traders are split between hoping for a low-float rebound and worrying about concentrated holdings, supply changes, and persistent selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI, Biotech, And Healthcare Catalysts Drive Momentum

Several emerging public companies are attracting attention as artificial intelligence, healthcare innovation, medical technology, and international commercialization strategies continue converging across the market. From AI-powered drug discovery and regenerative medicine expansion to precision dermatology and medical device innovation, recent developments highlight how smaller companies are positioning themselves around some of the fastest-growing sectors in healthcare and technology. $TGNT, $NXTS, $AZTR, $ADTX, $TNON, $PFE

Technological Innovations to Wage War Against Some of Medicine's Toughest Diseases

The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. $NTHI, $QURE, $ICCM, $CLPT, $ELTX, $AZTR

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for...

This Nano-Cap Pharma Stock Surged 80% Days After A Listing Warning — What’s Fueling the Rally?

Equity

The stock crossed its 100-DMA for the first time in more than eight months after announcing a private placement to raise over $31 million.

Small Caps Swing Big: Capital Raises Fuel AI, Biotech, and EV Ambitions

A flurry of financings, strategic pivots, and technology-driven initiatives is energizing the small-cap space, as companies tap capital markets to chase growth across AI, biotech, and next-generation transportation. $TGNT, $AZTR, $WNW, $UCAR, $JDZG

Nasdaq, S&P 500 Futures Take A Breather Ahead Of Massive Options Expiry: Why SMCI, NVDA, TSLA, UAMY, IBRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 


Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million Azitra Announces Pricing of Private Placement...

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE...

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders PR Newswire BRANFORD, Conn., March 5, 2026...

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates PR Newswire BRANFORD, Conn., Feb. 27, 2026...

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

Azitra Inc

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>The funding includes a $10.5 million upfront offering and up to $20.9 million from warrant exercises.</li><li>The company plans to use the proceeds to advance new protein and peptide research programs.</li><li>Last week, Azitra received a notice from the NYSE for failing to meet its minimum stockholders’ equity requirement of $6 million.</li></ul>Shares of Azitra Inc. (AZTR) surged more than 80% on Friday, crossing over its 100-day moving average for the first time since June 2025, after the biopharmaceutical firm announced a private placement to raise over $31 million.<figure class="image"><a class="st-link-external" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=AMEX%3AAZTR" target="_blank" rel="noopener noreferrer nofollow"><img src="https://news.stocktwits-cdn.com/aztr_jpg_0fe58a1f37.webp" alt="aztr.jpg" width="1345" height="849"></a></figure>Source: TradingViewOn Friday, <a href="https://stocktwits.com/symbol/AZTR">AZTR shares</a> recorded their biggest intraday gains since July 27, 2024.<h2 class="st-heading-2">Azitra To Advance New Protein And Peptide Research Programs</h2>Azitra said it is in the process of securing a financing deal worth up to $31.4 million to support its expansion into the cosmetic and cosmeceutical markets. The funding includes an initial $10.5 million offering through convertible preferred stock, with an additional $20.9 million tied to the potential exercise of warrants.The transaction is backed by institutional healthcare investors, including Stonepine Capital and Nantahala Capital.The company plans to use the proceeds to advance new protein and peptide research programs, using its microbial genetic engineering platform. Azitra aims to accelerate the development and commercialization of skincare solutions targeting issues such as dry skin and ageing.“We are confident these technologies offer an exciting new way to address the appearance of fine lines and wrinkles as well as dry, sensitive skin and eczema-like rashes,” said CFO Francisco Salva.<h2 class="st-heading-2">Azitra’s Listing Challenges</h2>Last week, Azitra received a notice from NYSE American LLC for failing to meet its minimum stockholders’ equity requirement of $6 million for companies with recent losses. The company has until April 1, 2027, to regain compliance, during which it will remain listed but will be subjected to regular reviews of its progress.According to Azitra’s latest financial update for the full-year ended Dec. 31, 2025, net loss widened to $11 million from $9 million a year earlier.The company also said it expects to report the topline Phase 1b results for its lead candidate, ATR12-351, for the treatment of Netherton, a rare and severe genetic skin disorder, in the second half of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday surge, retail sentiment has remained in the ‘bearish’ zone over the past 24 hours.One user said the stock could climb over $1 on the daily chart if the volume holds.<stembedurl>https://stocktwits.com/TonyStacks/message/648079663</stembedurl>Nearly 230 million shares changed hands in the first 20 minutes of trading, compared with an average of 1.8 million, according to Stocktwits data.Year-to-date, the stock has gained around 23%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/apple-aapl-stock-downtrend-200dma-retail-concern/cZ3XqspRILL">AAPL Stock’s Decline Leads It Toward 200-DMA For First Time In Over 7 Months – Retail Concerned Over Lack Of Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Is AZTR Stock Rising Today?

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$0.0715
Prev Close	$0.1176
Open	$0.1207
Dividend Yield	0.00%
50-Day Moving Average	$0.1465
Beta	1.40
Avg. Volume	709,137.54
PE Ratio	-0.05

52-Week High	$0.763
52-Week Low	$0.0518
Market Capitalization	$4.33M
EPS (Annual)	-$2.25
Price to Book	0.59
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AZTR Fundamentals